Cargando…

Reasons and Factors Contributing to Chinese Patients’ Preference for Ustekinumab in Crohn’s Disease: A Multicenter Cross-Sectional Study

Background and Aims: Ustekinumab (UST) was approved in China for treating moderate-to-severe Crohn’s disease (CD) in 2020. We aimed to identify the reasons and possible contributing factors for UST preference in Chinese patients with CD. Methods: We conducted a multicenter cross-sectional survey amo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yao, Lingya, Zhu, Xiao, Shao, Bule, Liu, Rongbei, Li, Zhilun, Wu, Lexi, Chen, Jin, Cao, Qian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8651007/ https://www.ncbi.nlm.nih.gov/pubmed/34887751 http://dx.doi.org/10.3389/fphar.2021.736149

Ejemplares similares

A Biosimilarity Study Between QX001S and Ustekinumab in Healthy Chinese Male Subjects
por: Gao, Lei, et al.
Publicado: (2021)

Clinical utility of ustekinumab in Crohn’s disease
por: Kotze, Paulo Gustavo, et al.
Publicado: (2018)

Hypersensitivity to IV Ustekinumab but Tolerance to Subcutaneous Ustekinumab in a Patient With Crohn's Disease
por: Krugliak Cleveland, Noa, et al.
Publicado: (2020)

Ustekinumab trough levels in children with Crohn’s disease refractory to anti-tumor necrosis factor agents: a prospective case series of off-label use
por: Bouhuys, Marleen, et al.
Publicado: (2023)

Rapid Resolution of Vulvar Crohn's Disease With Ustekinumab
por: Stoleru, Gianna, et al.
Publicado: (2020)

Successful Treatment of Oral Crohn’s Disease by Ustekinumab
por: Jukema, Jelmer B, et al.
Publicado: (2020)

Ustekinumab for Successful Treatment of Refractory Esophageal Crohn’s Disease
por: Barkin, Jodie A., et al.
Publicado: (2016)

Metastatic Vulval Crohn’s Disease With Good Outcome on Ustekinumab
por: Lim, Yizhe, et al.
Publicado: (2021)

Ustekinumab and Vedolizumab Dual Biologic Therapy in the Treatment of Crohn's Disease
por: Liu, Eddie Y., et al.
Publicado: (2017)

Cost-effectiveness of ustekinumab in moderate to severe Crohn’s disease in Sweden
por: Hansson-Hedblom, Amanda, et al.
Publicado: (2018)

Cost of Refractory Crohn’s Disease Before and After Ustekinumab Utilization
por: Rahme, Elham, et al.
Publicado: (2019)

Successful Drug Desensitization to Ustekinumab in a Patient with Crohn's Disease
por: Cohen, Barrie, et al.
Publicado: (2021)

Ustekinumab in Crohn’s Disease: New Data for Positioning in Treatment Algorithm
por: D’Amico, Ferdinando, et al.
Publicado: (2022)

Exacerbation of Atopic Dermatitis Associated with Ustekinumab Treatment in Crohn's Disease
por: Andres, Brendan, et al.
Publicado: (2022)

Refractory metastatic Crohn’s disease responsive to ustekinumab dose intensification
por: Xiao, Teresa L., et al.
Publicado: (2022)

Effectiveness and safety of vedolizumab for ulcerative colitis: a single-center retrospective real-world study in China
por: Huang, Kaituo, et al.
Publicado: (2023)

Profile of ustekinumab and its potential in patients with moderate-to-severe Crohn’s disease
por: Tuskey, Anne, et al.
Publicado: (2014)

Ustekinumab in treatment of Crohn’s disease: design, development, and potential place in therapy
por: Deepak, Parakkal, et al.
Publicado: (2016)

Posterior Reversible Encephalopathy Syndrome following Ustekinumab Induction for Crohn's Disease
por: Mishra, Avantika, et al.
Publicado: (2018)

High Immunogenicity to Influenza Vaccination in Crohn’s Disease Patients Treated with Ustekinumab
por: Doornekamp, Laura, et al.
Publicado: (2020)

Ustekinumab dose escalation improves clinical responses in refractory Crohn’s disease
por: Haider, Syedreza A., et al.
Publicado: (2020)

Ustekinumab Inhibits T Follicular Helper Cell Differentiation in Patients With Crohn’s Disease
por: Globig, Anna-Maria, et al.
Publicado: (2020)

An Australian Real-World Study of Treatment Persistence of Ustekinumab in Crohn’s Disease
por: Chien, Tzu Hsiang, et al.
Publicado: (2021)

Ustekinumab and Vedolizumab Are Equally Safe and Effective in Elderly Crohn’s Disease Patients
por: Gebeyehu, Gerum Gashaw, et al.
Publicado: (2022)

Ustekinumab Trough Concentrations Are Associated with Biochemical Outcomes in Patients with Crohn’s Disease
por: Straatmijer, Tessa, et al.
Publicado: (2023)

Ustekinumab trough concentration affects clinical and endoscopic outcomes in patients with refractory Crohn’s disease: a Chinese real-world study
por: Yao, Jia-yin, et al.
Publicado: (2021)

Extra intravenous Ustekinumab reinduction is an effective optimization strategy for patients with refractory Crohn’s disease
por: Yao, Jiayin, et al.
Publicado: (2023)

Real-world effectiveness and safety of ustekinumab induction therapy for Korean patients with Crohn’s disease: a KASID prospective multicenter study
por: Oh, Kyunghwan, et al.
Publicado: (2023)

Activation of PXR by Alpinetin Contributes to Abrogate Chemically Induced Inflammatory Bowel Disease
por: Yu, Zhilun, et al.
Publicado: (2020)

Codonopsis pilosula Polysaccharide Improved Spleen Deficiency in Mice by Modulating Gut Microbiota and Energy Related Metabolisms
por: Cao, Lingya, et al.
Publicado: (2022)

Hepatitis B Virus Reactivation and Mycobacterial Infections Associated With Ustekinumab: A Retrospective Study of an International Pharmacovigilance Database
por: Wang, Jingjing, et al.
Publicado: (2022)

Efficacy of ustekinumab against infliximab-induced psoriasis and arthritis associated with Crohn’s disease
por: Matsumoto, Satohiro, et al.
Publicado: (2018)

Next generation of biologics for the treatment of Crohn’s disease: an evidence-based review on ustekinumab
por: Jauregui-Amezaga, Aranzazu, et al.
Publicado: (2017)

Ustekinumab trough levels predicting laboratory and endoscopic remission in patients with Crohn’s disease
por: Hirayama, Hisashi, et al.
Publicado: (2022)

Ustekinumab for the treatment of refractory pediatric Crohn’s disease: a single-center experience
por: Cohen, Alexandra, et al.
Publicado: (2021)

Ustekinumab-Associated Posterior Reversible Encephalopathy Syndrome in a Patient With Crohn's Disease
por: Jordan, Ariel, et al.
Publicado: (2022)

Efficacy of Intravenous Ustekinumab Reinduction in Patients With Crohn’s Disease With a Loss of Response
por: Heron, Valerie, et al.
Publicado: (2022)

Ustekinumab Successfully Treats and Maintains Remission of Pyostomatitis Vegetans Associated with Crohn’s Disease
por: Abi Doumeth, Sarah, et al.
Publicado: (2020)

Response to Ustekinumab Therapy Is Associated with an Improvement of Nutritional Status in Patients with Crohn’s Disease †
por: Bertani, Lorenzo, et al.
Publicado: (2023)

Case Report: Malignant melanoma in a patient with Crohn’s disease treated with ustekinumab
por: Axiaris, Georgios, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_8rru8tm5fojakb4ivgabscc7m5